21.03.2013 Views

MARKS PUBLISHED FOR OPPOSITION

MARKS PUBLISHED FOR OPPOSITION

MARKS PUBLISHED FOR OPPOSITION

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

TM 206 OFFICIAL GAZETTE JANUARY 11, 2005<br />

CLASS 5—(Continued).<br />

SN 78-391,388. RUFUS, INC., EDISON, NJ. FILED 3-26-2004.<br />

THE MARK CONSISTS OF STANDARD CHARACTERS<br />

WITHOUT CLAIM TO ANY PARTICULAR FONT, STYLE,<br />

SIZE, OR COLOR.<br />

NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO<br />

USE "& COMPANY", APART FROM THE MARK AS<br />

SHOWN.<br />

<strong>FOR</strong> NUTRITIONAL SUPPLEMENTS <strong>FOR</strong> DOMESTIC<br />

PETS; MEDICATED PET GROOMING PRODUCTS,<br />

NAMELY PET SHAMPOO, PET LOTIONS, PET HAIR<br />

CONDITIONERS, AND PET CREAMS (U.S. CLS. 6, 18, 44,<br />

46, 51 AND 52).<br />

JOANNA DUKOVCIC, EXAMINING ATTORNEY<br />

SN 78-391,496. FMC CORPORATION, PHILADELPHIA, PA.<br />

FILED 3-26-2004.<br />

THE MARK CONSISTS OF STANDARD CHARACTERS<br />

WITHOUT CLAIM TO ANY PARTICULAR FONT, STYLE,<br />

SIZE, OR COLOR.<br />

<strong>FOR</strong> HERBICIDES <strong>FOR</strong> USE IN INDUSTRIAL APPLI-<br />

CATIONS (U.S. CLS. 6, 18, 44, 46, 51 AND 52).<br />

ODESSA BIBBINS, EXAMINING ATTORNEY<br />

CLASS 5—(Continued).<br />

SN 78-391,595. RECEPTOR BIOLOGIX, INC., ENCINITAS,<br />

CA. FILED 3-26-2004.<br />

THE MARK CONSISTS OF STANDARD CHARACTERS<br />

WITHOUT CLAIM TO ANY PARTICULAR FONT, STYLE,<br />

SIZE, OR COLOR.<br />

NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO<br />

USE "BIOLOGICS", APART FROM THE MARK AS SHOWN.<br />

<strong>FOR</strong> PHARMACEUTICAL PREPARATIONS, INCLUD-<br />

ING PHARMACEUTICALS <strong>FOR</strong> THE TREATMENT OF<br />

CANCER; PHARMACEUTICALS <strong>FOR</strong> THE TREAT-<br />

MENT OF DIABETES; PHARMACEUTICALS <strong>FOR</strong> THE<br />

TREATMENT OF INSULIN RESISTANCE SYNDROME;<br />

PHARMACEUTICALS <strong>FOR</strong> THE TREATMENT OF DIA-<br />

BETES-ASSOCIATED VASCULAR DISEASE; PHARMA-<br />

CEUTICALS <strong>FOR</strong> THE TREATMENT OF<br />

NEURODEGENERATIVE DISEASES; PHARMACEUTI-<br />

CALS <strong>FOR</strong> THE TREATMENT OF ANGIOGENESIS-<br />

RELATED DISEASES; PHARMACEUTICALS <strong>FOR</strong> THE<br />

TREATMENT OF ARTHRITIS; PHARMACEUTICALS<br />

<strong>FOR</strong> THE TREATMENT OF AUTOIMMUNE DISEASES;<br />

AND PHARMACEUTICALS <strong>FOR</strong> THE TREATMENT OF<br />

ENDOMETRIOSIS (U.S. CLS. 6, 18, 44, 46, 51 AND 52).<br />

ANNE FARRELL, EXAMINING ATTORNEY<br />

SN 78-392,341. FLEMING, TERRENCE, SAN DIEGO, CA.<br />

FILED 3-29-2004.<br />

THE MARK CONSISTS OF STANDARD CHARACTERS<br />

WITHOUT CLAIM TO ANY PARTICULAR FONT, STYLE,<br />

SIZE, OR COLOR.<br />

<strong>FOR</strong> DIETARY SUPPLEMENTS (U.S. CLS. 6, 18, 44, 46,<br />

51 AND 52).<br />

KELLEY WELLS, EXAMINING ATTORNEY

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!